Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InfuSystem Holdings (INFU) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for InfuSystem Holdings (INFU) over the last 11 years, with Q3 2025 value amounting to -$43000.0.

  • InfuSystem Holdings' Asset Writedowns and Impairment fell 11187.85% to -$43000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $601000.0, marking a year-over-year decrease of 4662.52%. This contributed to the annual value of $942000.0 for FY2024, which is 4542.29% down from last year.
  • InfuSystem Holdings' Asset Writedowns and Impairment amounted to -$43000.0 in Q3 2025, which was down 11187.85% from $123000.0 recorded in Q2 2025.
  • InfuSystem Holdings' 5-year Asset Writedowns and Impairment high stood at $597000.0 for Q1 2021, and its period low was -$169000.0 during Q3 2023.
  • Its 5-year average for Asset Writedowns and Impairment is $174578.9, with a median of $181000.0 in 2021.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 100000.0% in 2022, then surged by 76567.16% in 2024.
  • InfuSystem Holdings' Asset Writedowns and Impairment (Quarter) stood at $181000.0 in 2021, then soared by 166.85% to $483000.0 in 2022, then fell by 7.25% to $448000.0 in 2023, then tumbled by 41.07% to $264000.0 in 2024, then crashed by 116.29% to -$43000.0 in 2025.
  • Its Asset Writedowns and Impairment was -$43000.0 in Q3 2025, compared to $123000.0 in Q2 2025 and $257000.0 in Q1 2025.